{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T10:19:52Z","timestamp":1747736392630},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Fund Cultivation Special Project of Shanghai Children\u2019s Hospital","award":["2021YGZQ05"],"award-info":[{"award-number":["2021YGZQ05"]}]},{"name":"Scientific Research Fund of China Association Against Epilepsy","award":["CJ-A-2021-07","CX-2022-013"],"award-info":[{"award-number":["CJ-A-2021-07","CX-2022-013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Research on myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-associated disease (MOGAD) among Chinese children is relatively rare. Therefore, this study aimed to explore and analyze the clinical characteristics and prognoses of Chinese children with acquired demyelinating syndromes (ADSs) who tested positive or negative for MOG-Ab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The clinical data of children with MOGAD who were treated in the Department of Neurology at Shanghai Children's Hospital from January 2017 to October 2021 were retrospectively collected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 90 children with ADSs, 30 were MOG-Ab-positive, and 60 were MOG-Ab-negative. MOG-Ab-positive children experienced more prodromal infections than did MOG-Ab-negative children (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Acute disseminated encephalomyelitis was the most common ADSs in both groups. There were ten cases of a rebound increase in MOG-Ab titers. There were significant differences in the MOG titer-related prognosis and disease time course between the disease relapse group and the non-relapse group (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). Among the MOG-Ab-positive patients, the most affected brain areas detected via magnetic resonance imaging (MRI) were the temporal lobe, cerebellar hemispheres, brainstem, and periventricular lesions. The most common shapes of the lesions were commas, triangles, or patches. The average improvement time based on brain MRI was much longer in MOG-Ab-positive than in MOG-Ab-negative children (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). The initial treatment time correlated with the disease time course, and the prognosis may be affected by the disease time course and serum MOG-Ab titer (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The clinical characteristics and imaging features of ADSs differed between MOG-Ab-positive and MOG-Ab-negative children. In addition to existing treatment plans, additional diagnoses and treatment plans should be developed to reduce recurrence and improve the prognoses of children with MOGAD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12887-022-03679-3","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T12:03:05Z","timestamp":1668772985000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical characteristics and prognosis of pediatric myelin oligodendrocyte glycoprotein antibody-associated diseases in China"],"prefix":"10.1186","volume":"22","author":[{"given":"Xiaoang","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaona","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanmei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yucai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"3679_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0896-8411(89)90149-2","volume":"2","author":"R Lebar","year":"1989","unstructured":"Lebar R, Baudrimont M, Vincent C. Chronic experimental autoimmune encephalomyelitis in the guinea pig. Presence of anti-M2 antibodies in central nervous system tissue and the possible role of M2 autoantigen in the induction of the disease. J Autoimmun. 1989;2:115\u201332.","journal-title":"J Autoimmun"},{"key":"3679_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/jnnp-2014-308346","volume":"86","author":"M Baumann","year":"2015","unstructured":"Baumann M, Sahin K, Lechner C, Hennes EM, Schanda K, Mader S, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry. 2015;86:265\u201372.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3679_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-0037-1604404","volume":"49","author":"EM Hennes","year":"2018","unstructured":"Hennes EM, Baumann M, Lechner C, Rostasy K. MOG Spectrum Disorders and Role of MOG-Antibodies in Clinical Practice. Neuropediatrics. 2018;49:3\u201311.","journal-title":"Neuropediatrics"},{"key":"3679_CR4","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1177\/1352458513484547","volume":"19","author":"LB Krupp","year":"2013","unstructured":"Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013;19:1261\u20137.","journal-title":"Mult Scler"},{"key":"3679_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177\u201389.","journal-title":"Neurology"},{"key":"3679_CR6","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/cid\/cit458","volume":"57","author":"A Venkatesan","year":"2013","unstructured":"Venkatesan A, Tunkel AR, Bloch KC, Lauring AS, Sejvar J, Bitnun A, et al. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis. 2013;57:1114\u201328.","journal-title":"Clin Infect Dis"},{"key":"3679_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.msard.2019.06.002","volume":"33","author":"MS Boesen","year":"2019","unstructured":"Boesen MS, Jensen P, Born AP, Magyari M, Nilsson AC, Hoei-Hansen C, et al. Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 20082018: A nationwide, population-based cohort study. Mult Scler Relat Disord. 2019;33:162\u20137.","journal-title":"Mult Scler Relat Disord"},{"key":"3679_CR8","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","volume":"89","author":"EM Hennes","year":"2017","unstructured":"Hennes EM, Baumann M, Schanda K, Anlar B, Bajer-Kornek B, Blaschek A, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology. 2017;89:900\u20138.","journal-title":"Neurology"},{"key":"3679_CR9","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/dmcn.13703","volume":"60","author":"S Duignan","year":"2018","unstructured":"Duignan S, Wright S, Rossor T, Cazabon J, Gilmour K, Ciccarelli O, et al. Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes. Dev Med Child Neurol. 2018;60:958\u201362.","journal-title":"Dev Med Child Neurol"},{"key":"3679_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejpn.2020.10.006","volume":"29","author":"AL Bruijstens","year":"2020","unstructured":"Bruijstens AL, Lechner C, Flet-Berliac L, Deiva K, Neuteboom RF, Hemingway C, et al. E.U. paediatric MOG consortium consensus: Part 1 \u2013 Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020;29:2\u201313.","journal-title":"Eur J Paediatr Neurol"},{"key":"3679_CR11","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1177\/1352458519845112","volume":"26","author":"CL de Mol","year":"2020","unstructured":"de Mol CL, Wong Y, van Pelt ED, Wokke B, Siepman T, Neuteboom RF, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. 2020;26:806\u201314.","journal-title":"Mult Scler"},{"key":"3679_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.msard.2018.12.001","volume":"28","author":"J Zhou","year":"2019","unstructured":"Zhou J, Lu X, Zhang Y, et al. Follow-up study on Chinese children with relapsing MOG-IgG-associated central nervous system demyelination [J]. Mult Scler Relat Disord. 2019;28:4\u201310.","journal-title":"Mult Scler Relat Disord"},{"key":"3679_CR13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","volume":"77","author":"P Waters","year":"2020","unstructured":"Waters P, Fadda G, Woodhall M, O\u2019Mahony J, Brown RA, Castro DA, et al. Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. JAMA Neurol. 2020;77:82\u201393.","journal-title":"JAMA Neurol"},{"key":"3679_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/1352458515587751","volume":"22","author":"C Fernandez-Carbonell","year":"2016","unstructured":"Fernandez-Carbonell C, Vargas-Lowy D, Musallam A, Healy B, McLaughlin K, Wucherpfennig KW, et al. Clinical and MRI phenotype of children with MOG antibodies. Mult Scler. 2016;22:174\u201384.","journal-title":"Mult Scler"},{"key":"3679_CR15","doi-asserted-by":"publisher","first-page":"e705","DOI":"10.1212\/NXI.0000000000000705","volume":"7","author":"S Li","year":"2020","unstructured":"Li S, Ren H, Xu Y, Xu T, Zhang Y, Yin H, et al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study. Neurol Neuroimmunol Neuroinflamm. 2020;7:e705.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"3679_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3389\/fimmu.2017.00529","volume":"8","author":"P Peschl","year":"2017","unstructured":"Peschl P, Bradl M, H\u00f6ftberger R, Berger T, Reindl M. Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases. Front Immunol. 2017;8:529.","journal-title":"Front Immunol"},{"key":"3679_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.msard.2018.07.022","volume":"26","author":"B Konuskan","year":"2018","unstructured":"Konuskan B, Yildirim M, Gocmen R, Okur TD, Polat I, Kilic H, et al. Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders. Mult Scler Relat Dis. 2018;26:1\u20137.","journal-title":"Mult Scler Relat Dis"},{"key":"3679_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.msard.2018.01.007","volume":"20","author":"S Fan","year":"2018","unstructured":"Fan S, Xu Y, Ren H, Guan H, Feng F, Gao X, et al. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. Mult Scler Relat Disord. 2018;20:144\u201352.","journal-title":"Mult Scler Relat Disord"},{"key":"3679_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm. 2016;13:280.","journal-title":"J Neuroinflamm."},{"key":"3679_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","volume":"15","author":"M Reindl","year":"2019","unstructured":"Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. NAT REV NEUROL. 2019;15:89\u2013102.","journal-title":"NAT REV NEUROL"},{"key":"3679_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejpn.2020.11.001","volume":"29","author":"T Armangue","year":"2020","unstructured":"Armangue T, Capobianco M, de Chalus A, Laetitia G, Deiva K, et al. E.U. paediatric MOG consortium consensus: Part 3 - Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020;29:22\u201331.","journal-title":"Eur J Paediatr Neurol"},{"key":"3679_CR22","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.3390\/nu12051233","volume":"12","author":"G Mailhot","year":"2020","unstructured":"Mailhot G, White JH. Vitamin D and Immunity in Infants and Children. Nutrients. 2020;12:1233.","journal-title":"Nutrients"},{"key":"3679_CR23","doi-asserted-by":"publisher","first-page":"e731","DOI":"10.1212\/NXI.0000000000000731","volume":"7","author":"A Wegener-Panzer","year":"2020","unstructured":"Wegener-Panzer A, Cleaveland R, Wendel EM, Baumann M, Bertolini A, Hausler M, et al. Clinical and imaging features of children with autoimmune encephalitis and MOG antibodies. Neurol Neuroimmunol Neuroinflamm. 2020;7:e731.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"3679_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejpn.2020.10.007","volume":"29","author":"AL Bruijstens","year":"2020","unstructured":"Bruijstens AL, Breu M, Wendel E, Wassmer E, Lim M, Neuteboom RF, et al. E.U. paediatric MOG consortium consensus: Part 4 \u2013 Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020;29:32\u201340.","journal-title":"Eur J Paediatr Neurol"},{"key":"3679_CR25","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","volume":"90","author":"A Cobo-Calvo","year":"2018","unstructured":"Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. Clinical spectrum and prognosticvalue of CNS MOG autoimmunity in adults: The MOGADOR study. Neurology. 2018;90:e1858\u201369.","journal-title":"Neurology."},{"key":"3679_CR26","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1177\/1352458518811597","volume":"25","author":"LM Oliveira","year":"2019","unstructured":"Oliveira LM, Apostolos-Pereira SL, Pitombeira MS, Bruel TP, Callegaro D, Sato DK. Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. Mult Scler. 2019;25:1907\u201314.","journal-title":"Mult Scler"},{"key":"3679_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.4103\/jpn.JPN_185_16","volume":"12","author":"M Barbagallo","year":"2017","unstructured":"Barbagallo M, Vitaliti G, Pavone P, Romano C, Lubrano R, Falsaperla R. Pediatric autoimmune encephalitis. J. Pediatr Neurosci. 2017;12:130\u20134.","journal-title":"Pediatr Neurosci"},{"key":"3679_CR28","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1177\/1352458516631038","volume":"22","author":"M Baumann","year":"2016","unstructured":"Baumann M, Hennes EM, Schanda K, Karenfort M, Kornek B, Seidl R, et al. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases. Mult Scler. 2016;22:1821\u20139.","journal-title":"Mult Scler"},{"key":"3679_CR29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1212\/WNL.0000000000004117","volume":"89","author":"Y Hacohen","year":"2017","unstructured":"Hacohen Y, Mankad K, Chong WK, Barkhof F, Vincent A, Lim M, et al. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. Neurology. 2017;89:269\u201378.","journal-title":"Neurology"},{"key":"3679_CR30","first-page":"1280","volume":"266","author":"R Wynford-Thomas","year":"2019","unstructured":"Wynford-Thomas R, Jacob A, Tomassini V. Neurological update: MOG antibody disease. J Neurol J Neurol. 2019;266:1280\u20136.","journal-title":"J Neurol J Neurol"},{"key":"3679_CR31","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/dmcn.14267","volume":"61","author":"M Nosadini","year":"2019","unstructured":"Nosadini M, Granata T, Matricardi S, Freri E, Ragona F, Papetti L, et al. Relapse risk factors in anti-N-methyl-D-aspartate receptor encephalitis. Dev Med Child Neurol. 2019;61:1101\u20137.","journal-title":"Dev Med Child Neurol"},{"key":"3679_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","volume":"29","author":"AL Bruijstens","year":"2020","unstructured":"Bruijstens AL, Wendel E, Lechner C, Bartels F, Finke C, Breu M, et al. E.U. paediatric MOG consortium consensus: Part 5 \u2013 Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020;29:41\u201353.","journal-title":"Eur J Paediatr Neurol"},{"key":"3679_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jneuroim.2018.05.014","volume":"321","author":"L Chen","year":"2018","unstructured":"Chen L, Chen C, Zhong X, Sun X, Zhu H, Li X, et al. Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG: a multicenter study in South China. J Neuroimmunol. 2018;321:83\u201391.","journal-title":"J Neuroimmunol"},{"key":"3679_CR34","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fneur.2019.00868","volume":"10","author":"L Mao","year":"2019","unstructured":"Mao L, Yang L, Kessi M, He F, Zhang C, Wu L, Yin F, et al. Myelin Oligodendrocyte Glycoprotein (MOG) antibody diseases in children in central south china: clinical features, treatments, influencing factors, and outcomes. FRONT NEUROL. 2019;10:868.","journal-title":"FRONT NEUROL"},{"key":"3679_CR35","doi-asserted-by":"publisher","first-page":"e149411","DOI":"10.1371\/journal.pone.0149411","volume":"11","author":"K Kothur","year":"2016","unstructured":"Kothur K, Wienholt L, Tantsis EM, Earl J, Bandodkar S, et al. B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine\/Chemokines Are Elevated in MOG Antibody Associated Demyelination. PLoS ONE. 2016;11:e149411.","journal-title":"PLoS ONE"},{"key":"3679_CR36","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1002\/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D","volume":"28","author":"HP Eugster","year":"1998","unstructured":"Eugster HP, Frei K, Kopf M, Lassmann H, Fontana A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. EUR J IMMUNOL. 1998;28:2178\u201387.","journal-title":"EUR J IMMUNOL"},{"key":"3679_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.002","volume":"29","author":"M Baumann","year":"2020","unstructured":"Baumann M, Bartels F, Finke C, Adamsbaum C, Hacohen Y, Rost\u00e1sy K, Mog Consortium EUP, et al. EU paediatric MOG consortium consensus: Part 2 \u2013 Neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020;29:41\u201353.","journal-title":"Eur J Paediatr Neurol."},{"key":"3679_CR38","doi-asserted-by":"publisher","first-page":"1276983651","DOI":"10.1177\/1756286418762083","volume":"11","author":"MS Weber","year":"2018","unstructured":"Weber MS, Derfuss T, Metz I, Br\u00fcck W. Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Ther Adv Neurol Disord. 2018;11:1276983651.","journal-title":"Ther Adv Neurol Disord"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-022-03679-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-022-03679-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-022-03679-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T12:10:41Z","timestamp":1668773441000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-022-03679-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3679"],"URL":"https:\/\/doi.org\/10.1186\/s12887-022-03679-3","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"assertion":[{"value":"7 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involving human participants was reviewed and approved by the Ethics Review Committee, Children\u2019s Hospital of Shanghai\/Shanghai Children\u2019s Hospital, Shanghai Jiao Tong University (2022R026-E02). All study procedures were conducted in accordance with relevant guidelines and regulations.\u00a0All the participants\u2019 legal guardians and patients provided written informed consent. All participants provided appropriate permission for reproduced images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"666"}}